In Brief: Lynx Therapeutics
Executive Summary
Lynx Therapeutics: Glaxo Wellcome is terminating 1994 licensing agreement between Hayward, Calif.-based Lynx and the Wellcome Foundation that covers the development and marketing of Lynx' antisense drug candidate for the prevention of restenosis following coronary angioplasty or balloon dilation. Lynx reports Jan. 11 that the termination is effective March 17. Glaxo Wellcome says the phosphorothioate oligonucleotide is "no longer a good fit" with its pipeline. Lynx is studying the compound in a Phase I trial in Argentina, accruing 60 patients...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth